{"product_id":"the-cutaneous-lymphoid-proliferations-isbn-9781118776261","title":"The Cutaneous Lymphoid Proliferations","description":"\u003cp\u003eA masterful and thorough revision of the only single-source, authoritative reference on cutaneous lymphoproliferative disease.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eClassic reference for unsurpassed coverage of lymphocytic infiltrates of the human skin\u003c\/li\u003e \u003cli\u003eCovers a broad spectrum of topics ranging from the role of the immune system in the pathogenesis of cutaneous lymphocytic infiltrates to one describing   the immunohistochemica nd molecular aspects of lymphoid neoplasia. \u003c\/li\u003e \u003cli\u003eEach chapter contains an extensive array of  ‘clinical vignettes’ clearly showing the application of principles and treatment techniques discussed in the chapter\u003c\/li\u003e \u003cli\u003ePresents a succinct and logical approach to the diagnosis of most cutaneous lymphocytic infiltrates and discusses the  interplay between the immune system in  the propagation of lymphocytic infiltrates focusing on the role of iatrogenic and endogenous immune dysregulation. The molecular and cytogenetic basis of lymphoid neoplasia is considered in great detail.\u003c\/li\u003e \u003cli\u003eContains hundreds of full-color, high-quality clinical and histologic photographs, with over 200 new images in the new edition\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eAcknowledgments, viii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction to the Classification of Lymphoma 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eKiel Lukes–Collins, and Working Formulation classifications 1\u003c\/p\u003e \u003cp\u003eWHO, REAL, EORTC, and the Combined WHO\/EORTC classifications 2\u003c\/p\u003e \u003cp\u003eSummary 7\u003c\/p\u003e \u003cp\u003eReferences 8\u003c\/p\u003e \u003cp\u003eAppendix: Definitions of key terms and techniques 9\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 The Therapy of Cutaneous T Cell Lymphoma 14\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eBenjamin H. Kaffenberger, Mark A. Bechtel, and Pierluigi Porcu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 14\u003c\/p\u003e \u003cp\u003eDiagnostic work-up and staging procedures 14\u003c\/p\u003e \u003cp\u003eCTCL therapies 15\u003c\/p\u003e \u003cp\u003eGoals of therapy in advanced-stage CTCL 16\u003c\/p\u003e \u003cp\u003eExtracorporeal photopheresis (ECP) 17\u003c\/p\u003e \u003cp\u003eInterferons 17\u003c\/p\u003e \u003cp\u003eRetinoids 17\u003c\/p\u003e \u003cp\u003eImmunotoxins 18\u003c\/p\u003e \u003cp\u003eMonoclonal antibodies 18\u003c\/p\u003e \u003cp\u003eHistone deacetylase inhibitors (HDACi) 19\u003c\/p\u003e \u003cp\u003eAntibody drug conjugates (ADC) 19\u003c\/p\u003e \u003cp\u003eCytotoxic chemotherapy 19\u003c\/p\u003e \u003cp\u003eInvestigational therapies 20\u003c\/p\u003e \u003cp\u003eTLR agonists and cytokines 20\u003c\/p\u003e \u003cp\u003eAllogeneic hematopoietic stem cell transplantation (allo-HSCT) 20\u003c\/p\u003e \u003cp\u003eReferences 21\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Molecular Analysis in Cutaneous Lymphoid Proliferation 23\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eShabnam Momtahen, Cynthia Magro, and Carl Morrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 23\u003c\/p\u003e \u003cp\u003eImmunoglobulin and T cell receptor structure 23\u003c\/p\u003e \u003cp\u003ePCR design for determination of clonality 24\u003c\/p\u003e \u003cp\u003eDetection of PCR products for clonality 24\u003c\/p\u003e \u003cp\u003eEvaluation of results 25\u003c\/p\u003e \u003cp\u003eThe value and utility of molecular diagnostics in primary cutaneous lymphomas 26\u003c\/p\u003e \u003cp\u003eLimitations of clonality assessment by PCR 27\u003c\/p\u003e \u003cp\u003eCase vignettes 29\u003c\/p\u003e \u003cp\u003eReferences 36\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Benign Lymphocytic Infiltrates 37\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 37\u003c\/p\u003e \u003cp\u003eSpongiotic and eczematous dermatitis 37\u003c\/p\u003e \u003cp\u003eOther spongiotic\/eczematous tissue reactions 40\u003c\/p\u003e \u003cp\u003eOther causes of subacute eczematous dermatitis 40\u003c\/p\u003e \u003cp\u003eInterface dermatitis: cell-poor vacuolar interface dermatitis 42\u003c\/p\u003e \u003cp\u003eInterface dermatitis: lichenoid pattern 46\u003c\/p\u003e \u003cp\u003eDiffuse and nodular lymphocytic dermal infiltrates without atypia 51\u003c\/p\u003e \u003cp\u003eDiffuse and nodular lymphocytic infiltrates associated with autoimmune disease 53\u003c\/p\u003e \u003cp\u003eReferences 57\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Reactive Lymphomatoid Tissue Reactions Mimicking Cutaneous T and B Cell Lymphoma 59\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLymphomatoid drug eruptions 59\u003c\/p\u003e \u003cp\u003eMolecular profile of lymphomatoid drug eruptions 61\u003c\/p\u003e \u003cp\u003ePathogenetic basis of lymphomatoid drug reactions 62\u003c\/p\u003e \u003cp\u003eReactive lymphomatoid lesions encountered in lesions of collagen vascular disease 63\u003c\/p\u003e \u003cp\u003eAngiomatous Variants of Pseudolymphoma 67\u003c\/p\u003e \u003cp\u003eCase vignettes 69\u003c\/p\u003e \u003cp\u003eReferences 86\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Precursor Lesions of Cutaneous T Cell Lymphoma 89\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCutaneous T cell lymphoid dyscrasia 89\u003c\/p\u003e \u003cp\u003eLarge plaque parapsoriasis 90\u003c\/p\u003e \u003cp\u003eHypopigmented interface T cell dyscrasia: a unique indolent T cell dyscrasia 91\u003c\/p\u003e \u003cp\u003ePigmented purpuric dermatosis (PPD) 92\u003c\/p\u003e \u003cp\u003ePityriasis lichenoides 94\u003c\/p\u003e \u003cp\u003eIdiopathic erythroderma (pre-Sézary) 96\u003c\/p\u003e \u003cp\u003eSyringolymphoid hyperplasia with alopecia 96\u003c\/p\u003e \u003cp\u003eFolliculotropic T cell lymphocytosis\/pilotropic T cell dyscrasia 97\u003c\/p\u003e \u003cp\u003eIdiopathic follicular mucinosis\/alopecia mucinosa 98\u003c\/p\u003e \u003cp\u003eKeratoderma-like T cell dyscrasia 99\u003c\/p\u003e \u003cp\u003eAtypical lymphocytic lobular panniculitis 100\u003c\/p\u003e \u003cp\u003eCase vignettes 102\u003c\/p\u003e \u003cp\u003eReferences 132\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Marginal Zone Lymphoma and Other Related Post Germinal Center B Cell Lymphoproliferative Disorders of The Skin 134\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMarginal zone lymphoma 134\u003c\/p\u003e \u003cp\u003eBlastic marginal zone lymphoma 140\u003c\/p\u003e \u003cp\u003eEpidermotropic marginal zone lymphoma 140\u003c\/p\u003e \u003cp\u003eCastleman disease 141\u003c\/p\u003e \u003cp\u003ePrimary cutaneous plasmacytoma 142\u003c\/p\u003e \u003cp\u003eCase vignettes 145\u003c\/p\u003e \u003cp\u003eReferences 166\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Primary Cutaneous Follicle Center Cell Lymphoma 169\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 169\u003c\/p\u003e \u003cp\u003ePathology 169\u003c\/p\u003e \u003cp\u003ePhenotypic profile 171\u003c\/p\u003e \u003cp\u003eMolecular studies 172\u003c\/p\u003e \u003cp\u003ePathogenesis 172\u003c\/p\u003e \u003cp\u003eCytogenetics 172\u003c\/p\u003e \u003cp\u003eCase vignettes 174\u003c\/p\u003e \u003cp\u003eAdditional molecular and cytogenetic study 185\u003c\/p\u003e \u003cp\u003eReferences 186\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Primary Cutaneous Diffuse Large B-Cell Lymphoma Including the Leg Type and Precursor B Cell Lymphoblastic Lymphoma 187\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePrimary cutaneous diffuse large B cell lymphoma 187\u003c\/p\u003e \u003cp\u003eSystemic diffuse large B cell lymphomas with a propensity to involve the skin 197\u003c\/p\u003e \u003cp\u003eCase vignettes 200\u003c\/p\u003e \u003cp\u003eAdditional light microscopic, phenotypic, molecular, cytogenetic studies 210\u003c\/p\u003e \u003cp\u003eReferences 215\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Intravascular Lymphoma 218\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 218\u003c\/p\u003e \u003cp\u003eLight microscopic findings 219\u003c\/p\u003e \u003cp\u003ePhenotypic profile 219\u003c\/p\u003e \u003cp\u003eMolecular and cytogenetic studies 219\u003c\/p\u003e \u003cp\u003ePathogenesis 219\u003c\/p\u003e \u003cp\u003eDifferential diagnosis 219\u003c\/p\u003e \u003cp\u003eIntravascular anaplastic large cell lymphoma 219\u003c\/p\u003e \u003cp\u003eBenign intravascular proliferations of histiocytes and reactive T cells 220\u003c\/p\u003e \u003cp\u003eCase vignettes 221\u003c\/p\u003e \u003cp\u003eReferences 224\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Cutaneous Mantle Cell Lymphoma 225\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 225\u003c\/p\u003e \u003cp\u003eLight microscopic findings 225\u003c\/p\u003e \u003cp\u003ePhenotypic profile 226\u003c\/p\u003e \u003cp\u003eMolecular studies 227\u003c\/p\u003e \u003cp\u003eCytogenetic profile 227\u003c\/p\u003e \u003cp\u003ePathogenesis 227\u003c\/p\u003e \u003cp\u003eCase vignettes 229\u003c\/p\u003e \u003cp\u003eAdditional molecular and cytogenetic studies 233\u003c\/p\u003e \u003cp\u003eReferences 234\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Mycosis Fungoides and Sézary Syndrome 236\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDefinition 236\u003c\/p\u003e \u003cp\u003eMycosis fungoides 236\u003c\/p\u003e \u003cp\u003eSézary syndrome and erythrodermic mycosis fungoides 243\u003c\/p\u003e \u003cp\u003eLarge cell transformation of mycosis fungoides 251\u003c\/p\u003e \u003cp\u003eExtracutaneous involvement in mycosis fungoides 254\u003c\/p\u003e \u003cp\u003eCase vignettes 259\u003c\/p\u003e \u003cp\u003eReferences 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 CD30-Positive Lymphoproliferative Disorders Including Lymphomatoid Papulosis, Borderline CD30-Positive Lymphoproliferative Disease, Anaplastic Large Cell Lymphoma, and T-Cell-Rich CD30-Positive Large B Cell Lymphoma 274\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 274\u003c\/p\u003e \u003cp\u003eLymphomatoid papulosis 274\u003c\/p\u003e \u003cp\u003eCD8+ lymphomatoid papulosis, including the type D variant 278\u003c\/p\u003e \u003cp\u003eType E lymphomatoid papulosis (Case vignette 15) 278\u003c\/p\u003e \u003cp\u003eBorderline CD30-positive lymphoproliferative disorders (type C LYP) (Case vignette 9) 279\u003c\/p\u003e \u003cp\u003eLymphomatoid papulosis with a rearrangement of chromosome 6p25.3 279\u003c\/p\u003e \u003cp\u003eCutaneous anaplastic large cell lymphoma 280\u003c\/p\u003e \u003cp\u003eSmall cell ALCL 282\u003c\/p\u003e \u003cp\u003eAdditional unusual histologic variants of anaplastic large cell lymphoma 282\u003c\/p\u003e \u003cp\u003eBreast-implant-associated anaplastic large cell lymphoma 282\u003c\/p\u003e \u003cp\u003eIntravascular anaplastic large cell lymphoma 282\u003c\/p\u003e \u003cp\u003eSarcomatoid anaplastic large cell lymphoma (Case vignette 14) 283\u003c\/p\u003e \u003cp\u003eCD30-positive large B cell lymphoma 285\u003c\/p\u003e \u003cp\u003eCase vignettes 286\u003c\/p\u003e \u003cp\u003eReferences 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 CD4+ Peripheral T Cell Lymphoma, Not Otherwise Specified, Including Primary Cutaneous Cd4+ Small\/Medium-Sized Pleomorphic T Cell Lymphoma 312\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 312\u003c\/p\u003e \u003cp\u003ePrimary cutaneous CD4+ small\/medium-sized pleomorphic T cell lymphoma 312\u003c\/p\u003e \u003cp\u003eCD30-negative large cell T cell lymphoma 313\u003c\/p\u003e \u003cp\u003eCutaneous follicular helper T cell lymphoma 314\u003c\/p\u003e \u003cp\u003eOverview of overall prognosis of primary cutaneous peripheral T cell lymphoma, unspecified 315\u003c\/p\u003e \u003cp\u003eEvolution of the nomenclature of primary cutaneous CD4+ small\/medium-sized pleomorphic T cell lymphoma 319\u003c\/p\u003e \u003cp\u003eCase vignettes 320\u003c\/p\u003e \u003cp\u003eReferences 333\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Subcutaneous Panniculitis-Like T Cell Lymphoma 334\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 334\u003c\/p\u003e \u003cp\u003eMorphology 336\u003c\/p\u003e \u003cp\u003ePhenotype 337\u003c\/p\u003e \u003cp\u003eMolecular studies 337\u003c\/p\u003e \u003cp\u003eDifferential diagnosis 337\u003c\/p\u003e \u003cp\u003eCase vignettes 340\u003c\/p\u003e \u003cp\u003eReferences 349\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 CD8 T Cell Lymphoproliferative Disease of the Skin 351\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOverview 351\u003c\/p\u003e \u003cp\u003eIntroduction 351\u003c\/p\u003e \u003cp\u003eClassification of primary CD8+ cutaneous T cell lymphomas 352\u003c\/p\u003e \u003cp\u003eHistomorphology of primary cutaneous CD8+ T cell lymphoma: primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma, and CD8+ variants of peripheral T cell lymphoma, NOS, including primary cutaneous CD8+ granulomatous T cell lymphoma 353\u003c\/p\u003e \u003cp\u003eCD8 variant of lymphomatoid papulosis and other related CD30-positive T cell lymphoproliferative disorders of CD8 subtype 354\u003c\/p\u003e \u003cp\u003eLight microscopic findings 354\u003c\/p\u003e \u003cp\u003eIndolent CD8 positive lymphoid proliferation of the face and other body sites including acral surfaces 355\u003c\/p\u003e \u003cp\u003eCD8 prolymphocytic leukemia 355\u003c\/p\u003e \u003cp\u003eCD8 pseudolymphoma related to underlying HIV disease 356\u003c\/p\u003e \u003cp\u003eDrug-associated CD8+ pseudolymphoma 356\u003c\/p\u003e \u003cp\u003eActinic reticuloid as a unique form of CD8+pseudolymphoma 356\u003c\/p\u003e \u003cp\u003eCase vignettes 357\u003c\/p\u003e \u003cp\u003eReferences 375\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Nasal and Related Extranodal Natural Killer Cell\/T Cell Lymphomas and Blastic Plasmacytoid Dendritic Cell Neoplasm 377\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 377\u003c\/p\u003e \u003cp\u003eBiology of NK and NK-like T cells 377\u003c\/p\u003e \u003cp\u003eNK\/T-cell lymphoma 379\u003c\/p\u003e \u003cp\u003eNasal NK\/T cell lymphoma 379\u003c\/p\u003e \u003cp\u003eNasal type NK\/T cell lymphoma 380\u003c\/p\u003e \u003cp\u003eAggressive NK cell lymphoma 380\u003c\/p\u003e \u003cp\u003eRole of Epstein–Barr virus in the evolution of NK\/T cell lymphomas 382\u003c\/p\u003e \u003cp\u003eBlastic plasmacytoid dendritic cell neoplasm 382\u003c\/p\u003e \u003cp\u003eCD56-positive γ δ lymphoma involving the subcutaneous fat 383\u003c\/p\u003e \u003cp\u003eChronic granular lymphocytosis\/large granular cell leukemia 384\u003c\/p\u003e \u003cp\u003eNatural killer-like CD4+ T cell lymphoma 384\u003c\/p\u003e \u003cp\u003eEBV-associated NK\/T cell lymphomas of the elderly 385\u003c\/p\u003e \u003cp\u003eHydroa vaccineforme (HV)-like lymphoma 385\u003c\/p\u003e \u003cp\u003eCutaneous intravascular NK T cell lymphoma 386\u003c\/p\u003e \u003cp\u003eCase vignettes 387\u003c\/p\u003e \u003cp\u003eReferences 401\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Primary Cutaneous γ δ T Cell Lymphoma 404\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 404\u003c\/p\u003e \u003cp\u003eCase vignettes 409\u003c\/p\u003e \u003cp\u003eAdditional supplemental figures 411\u003c\/p\u003e \u003cp\u003eReferences 414\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Epstein–Barr Virus-Associated Lymphoproliferative Disease 415\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 415\u003c\/p\u003e \u003cp\u003eHydroa vacciniforme-like EBV-associated T cell lymphoproliferative disease\/mosquito bite hypersensitivity 416\u003c\/p\u003e \u003cp\u003eEBV+ cutaneous B cell lymphoproliferative disorder of the elderly 420\u003c\/p\u003e \u003cp\u003eEBV-associated mucocutaneous ulcer 421\u003c\/p\u003e \u003cp\u003eEBV + T cell lymphoproliferative disease of the elderly 421\u003c\/p\u003e \u003cp\u003eGeneral principles regarding EBV-associated lymphomagenesis 421\u003c\/p\u003e \u003cp\u003ePathogenetic link between EBV-associated B cell lymphoma and iatrogenic immune dysregulation related to either methotrexate or cyclosporine 421\u003c\/p\u003e \u003cp\u003eCase vignettes 423\u003c\/p\u003e \u003cp\u003eReferences 432\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Hodgkin Lymphoma of the Skin 435\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 435\u003c\/p\u003e \u003cp\u003eSubtypes of Hodgkin lymphoma 436\u003c\/p\u003e \u003cp\u003eReferences 447\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Chronic Lymphocytic Leukemia of B Cell and T Cell Prolymphocytic Leukemia 449\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eB cell chronic lymphocytic leukemia 449\u003c\/p\u003e \u003cp\u003eT cell prolymphocytic leukemia 452\u003c\/p\u003e \u003cp\u003eCase vignettes 455\u003c\/p\u003e \u003cp\u003eReferences 471\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Adult T Cell Leukemia\/Lymphoma 473\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 473\u003c\/p\u003e \u003cp\u003ePathology 474\u003c\/p\u003e \u003cp\u003ePhenotypic studies 475\u003c\/p\u003e \u003cp\u003ePathogenesis 475\u003c\/p\u003e \u003cp\u003eInfective dermatitis of childhood 476\u003c\/p\u003e \u003cp\u003eCase vignettes 477\u003c\/p\u003e \u003cp\u003eReferences 484\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Angioimmunoblastic Lymphadenopathy\/Angioimmunoblastic T Cell Lymphoma 486\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical features 486\u003c\/p\u003e \u003cp\u003eLight microscopic findings 487\u003c\/p\u003e \u003cp\u003ePhenotypic studies 488\u003c\/p\u003e \u003cp\u003eMolecular studies 488\u003c\/p\u003e \u003cp\u003ePathogenesis 489\u003c\/p\u003e \u003cp\u003eCase vignettes 491\u003c\/p\u003e \u003cp\u003eReferences 497\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Lymphomatoid Granulomatosis 499\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 499\u003c\/p\u003e \u003cp\u003eClinical features 499\u003c\/p\u003e \u003cp\u003eHistopathology 500\u003c\/p\u003e \u003cp\u003eHistogenesis 501\u003c\/p\u003e \u003cp\u003eClonality studies 501\u003c\/p\u003e \u003cp\u003eDifferential diagnosis 501\u003c\/p\u003e \u003cp\u003eTreatment 502\u003c\/p\u003e \u003cp\u003eCase vignette 503\u003c\/p\u003e \u003cp\u003eReferences 506\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Cutaneous Infiltrates of Myeloid Derivation 507\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 507\u003c\/p\u003e \u003cp\u003eLeukemia cutis 507\u003c\/p\u003e \u003cp\u003eClonal histiocytopathy syndromes 509\u003c\/p\u003e \u003cp\u003eHistiocytopathy of factor XIIIA perivascular dermal dendritic cell origin 514\u003c\/p\u003e \u003cp\u003eCase vignettes 517\u003c\/p\u003e \u003cp\u003eReferences 537\u003c\/p\u003e \u003cp\u003eIndex 541\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCynthia M. Magro\u003c\/b\u003e MD\u003cbr\u003eProfessor of Pathology and Laboratory Medicine\u003cbr\u003eDepartment of Pathology, Cornell University\u003cbr\u003eWeill Cornell Medicine\u003cbr\u003eNew York, NY, USA\u003c\/p\u003e \u003cp\u003e\u003cb\u003eA. Neil Crowson\u003c\/b\u003e MD\u003cbr\u003eClinical Professor of Dermatology, Pathology, and Surgery\u003cbr\u003eDirector of Dermatopathology at the University of Oklahoma and Regional Medical Laboratory\u003cbr\u003ePresident of Pathology Laboratory Associates\u003cbr\u003eTulsa, OK, USA\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMartin C. Mihm\u003c\/b\u003e MD\u003cbr\u003eClinical Professor of Pathology and Dermatology, Harvard Medical School\u003cbr\u003eDirector of Melanoma Program, Dermatology, Brigham and Women’s Hospital\u003cbr\u003eCo-Director of Melanoma Program, Dana-Farber and Brigham and Women’s Cancer Center\u003cbr\u003eDirector, Mihm Cutaneous Pathology Consultative Service\u003cbr\u003eBrigham and Women’s Hospital\u003cbr\u003eBoston, MA, USA\u003c\/p\u003e \u003cp\u003e\u003ci\u003eThe Cutaneous Lymphoid Proliferations\u003c\/i\u003e is the go-to reference for a complete, authoritative treatment of the clinical features, phenotype, pathogenesis, histopathology, diagnosis, and treatment of lymphocytic infiltrates of the skin. This second edition incorporates the latest findings from the fields of light microscopy, immunohistochemistry, and flow cytometry and brings readers up to date with the most current thinking in the field.\u003c\/p\u003e \u003cp\u003eThe book starts off with a clinical atlas and introduction to the ontogeny and biology of the lymphoid system. Next, the authors explore novel molecular approaches to the diagnosis of cutaneous lymphoid proliferation and benign lymphocytic infiltrates. The remaining chapters concentrate on major inflammatory skin diseases and lymphoproliferative disorders, including chronic lymphocytic leukemia, lupus, adult T cell leukemia, and primary cutaneous Hodgkin's disease. \u003c\/p\u003e \u003cp\u003eThe title:\u003c\/p\u003e \u003cp\u003e-  Discusses additional hematologic dyscrasias, including double hit B cell lymphoma, type D lymphomatoid papulosis, myxoid anaplastic large cell lymphoma, and myeloid dendritic cell leukemia\u003c\/p\u003e \u003cp\u003e- Contains brand new content on paraneoplastic cutaneous manifestations of lymphoproliferative disease, and myelomonocytic dyscrasias,  including terminally differentiated histiocytopathies such as Langerhans cell histiocytopathy including Langerhans cell sarcoma and indeterminate cell proliferative disorder\u003c\/p\u003e \u003cp\u003e- Covers the role of the immune system in the pathogenesis of cutaneous disease\u003c\/p\u003e \u003cp\u003e- Contains numerous new clinical vignettes that clearly show the application of principles and treatment techniques discussed in the chapter\u003c\/p\u003e \u003cp\u003e- Discusses the relationships between therapeutic drugs and cutaneous eruptions and carefully notes important drug reactions\u003c\/p\u003e \u003cp\u003e- Contains hundreds of full-color, high-quality clinical and histologic photographs, with over 100 new\u003c\/p\u003e A classic reference for unsurpassed coverage of lymphocytic infiltrates of the human skin. ","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990202990821,"sku":"NP9781118776261","price":374.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118776261.jpg?v=1761786889","url":"https:\/\/k12savings.com\/es\/products\/the-cutaneous-lymphoid-proliferations-isbn-9781118776261","provider":"K12savings","version":"1.0","type":"link"}